Davita Inc vs Ross Stores, Inc. — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Ross Stores, Inc. trades at $226 (market cap $72.05B). The key difference: Ross Stores, Inc. is far larger — about 6.4× Davita Inc's market cap, and Ross Stores, Inc. pays a 0.79% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Ross Stores, Inc. for 48 Days on average.
| DVA | ROST | |
|---|---|---|
Market Cap | $11.28B | $72.05B |
Volume | 650,294 | 1,674,861 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $255.23 |
52-Week Low | $103.87 | $147.71 |
Typical Hold Time | 113 Days | 48 Days |
Enterprise Value | $24.00B | $72.50B |
Dividend Yield | — | 0.79% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Ross Stores (ROST) trades at $225.20, up 0.44% today, showing strong fundamental performance with consistent earnings beats and robust profitability metrics including 42.63% ROE and 10.85% net margin. The stock faces technical headwinds with a bearish signal from moving averages, trading near support at $224. Recent news highlights store expansion initiatives and strong closeout supply benefits as the company captures value-conscious shoppers amid competitive retail pressures.
ROST presents a compelling investment case with analyst consensus pointing to 22% upside to the $274.14 price target, supported by strong earnings momentum and expanding margins. Key risks include retail competition, cost pressures, and macroeconomic sensitivity, but the company's value-focused strategy and operational discipline position it well for sustained growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →